Study for Whole Genome and Exome Sequencing to 2024

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered.

Find out all about it in the comprehensive report of Whole Genome Sequencing.

The complete genome of the COVID virus is included as an example of the work being done.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead?

What’s holding the industry back? Where are the over 800 locations that have high throughput devices?

The plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players.

New consumers, new technologies, new specializations.

In a situation reminiscent of the birth of the internet industry a wide range of well-funded players are racing for market share on a truly global stage.

The report forecasts the market size out to 2023. This report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression?

Find out about the technology in readily understood terms that explain the jargon.

What are the issues? Find the opportunities and pitfalls.

Understand growth expectations and the ultimate market forecasts for the next five years.

For more information, visit www.researchandmarkets.com